

# Specialty Guideline Management

## Abecma

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Abecma	idecabtagene vicleucel

### Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-approved Indications

Abecma is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

All other indications are considered experimental/investigational and not medically necessary.

### Documentation

Submission of the following information is necessary to initiate the prior authorization review: chart notes, medical record documentation or claims history supporting previous lines of therapy.

# Coverage Criteria

## Multiple Myeloma

Authorization of 3 months may be granted for treatment of relapsed or refractory multiple myeloma in members 18 years of age and older when all of the following are met:

- The member has received prior treatment with at least two lines of therapy, including at least one drug from each of the following categories:
  - Immunomodulatory agent
  - Proteasome inhibitor
  - Anti-CD 38 monoclonal antibody
- The member has not received a previous treatment course of the requested medication or another chimeric antigen receptor (CAR) T-cell therapy directed at any target.
- The member has an ECOG performance status of 0 to 2.
- The member has adequate and stable kidney, liver, pulmonary and cardiac function.
- The member has no history or presence of clinically relevant central nervous system (CNS) pathology.
- The member does not have clinically significant active infection.
- The member does not have active graft versus host disease.
- The member does not have an active inflammatory disorder.

## References

1. Abecma [package insert]. Summit, NJ: Celgene Corporation; April 2024.
2. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 Feb 25;384(8):705-716.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma. Version 4.2024. Accessed May 10, 2024.
4. Patel U, Oluwale OO, Kassim A, et al. Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies. J Clin Oncol. 2023;41(16):e20049.